It is well established that pregnancies protect against breast cancer; however, the mechanism involved is not completely understood. We investigated the influence of parity on hormonal and proliferation markers in benign tissue from tumor blocks of breast cancer cases. Women with breast cancer were recruited from a case-control study nested within the Multiethnic Cohort study. Tissue microarrays of benign tissue cores were available for 159 participants. Immunostaining for estrogen receptor a (ERa) and ERb, progesterone receptor, human epidermal growth factor receptor 2 (Her2/neu), Ki-67, and proliferating cell nuclear antigen (PCNA) in epithelial tissue was evaluated by a pathologic expert. We applied logistic regression models to examine marker expression by parity (0, 1-2, and Z 3 live births with adjustment for age at diagnosis and BMI). Of the 159 women, 24 were nulliparous, 63 had one or two live births, and 72 had three or more live births. Inverse associations were observed between parity and expression of ERa (P trend = 0.02) and PCNA (P trend = 0.04). Among nulliparous women, 45.5% were ERa positive in contrast to 18.0 and 18.9% of women with one or two and at least three live births, respectively. The respective values for PCNA were 56.5, 44.3, and 31.1%. No associations were detected for ERb, progesterone receptor, Her2/neu, and Ki-67. The current findings suggest that pregnancies may protect against breast cancer by reducing susceptibility to estrogenic stimuli and proliferative activity as assessed by the expression of ERa and PCNA in breast tissue.
Introduction
Epidemiological studies across ethnic groups and regions suggest that parity is protective against breast cancer, specifically, estrogen receptor (ER)-positive breast cancer (Collaborative Group on Hormonal Factors in Breast Cancer, 2002; Britt et al., 2007) ; however, its mechanism is not fully understood. One or more pregnancies may induce physiological changes in the breast that, in turn, make the epithelial tissue less susceptible to malignant transformation in the future, especially if the pregnancies occur at early ages (Russo et al., 2005; Britt et al., 2007) . Studies on rodent indicate that pregnancy is profoundly protective against both the tumor-initiating effects of DNA-damaging carcinogens, such as dimethylbenzanthracene or ionizing radiation, and the tumor-promoting effects of endogenous or exogenous steroid hormones (Medina, 2005) . During pregnancy, undifferentiated epithelial cells, which make up most of the breast lobules of nulliparous women, develop into mature epithelia (Russo et al., 2005) . Highly differentiated cells are thought to be more resistant to carcinogenesis. Such transformation may be observable in hormonal and proliferation markers of breast tissue of parous women. For example, gene expression analyses in the mammary gland of 28 female cynomolgus macaques in different life phases showed distinct patterns during pregnancy and lactation including changes in ER and progesterone receptors (PRs) (Stute et al., 2012) . As shown in previous reports of small numbers of premenopausal women (Battersby et al., 1992; Taylor et al., 2009 ), the expression of histopathologic markers, such as ER and PR, may be lower in parous than in nulliparous women. The presence of these hormone receptors influences tumor growth in the breast in response to estrogenic stimuli; ERa promotes proliferative activity, whereas ERb appears be more antiproliferative by stimulating cell differentiation (Barkhem et al., 1998; Britt et al., 2007; Fox et al., 2008) . The expression of PR, which has subtypes PRA and PRB with possible opposing effects, is regulated by ERa in the presence of estrogens and is a sensitive indicator of estrogenic effects in cells (Potter et al., 1995; Nardulli et al., 1988) . ER and PR expression status also serve as prognostic factors and help in the selection of the appropriate breast cancer treatment. Other immunohistochemical markers associated with breast cancer prognosis include those that detect specific nuclear antigens, such as human epidermal growth factor receptor 2 (HER2/neu), Ki-67, and proliferating cell nuclear antigen (PCNA). These proteins are involved in cell proliferation and their expression indicates cancer growth and progression (Schwartz et al., 1993) . In contrast to ER or PR, their relation with parity has not been investigated. To add to the limited knowledge of how parity may protect against breast cancer risk by altering breast tissue, we explored the expression status of these markers in benign tissue from tumor blocks of breast cancer patients in the Hawaii component of the Multiethnic Cohort (MEC) study.
Materials and methods

Study population
Women with breast cancer were recruited from a casecontrol study (Maskarinec et al., 2005) investigating mammographic density nested in the MEC study (Kolonel et al., 2000) . Benign tissue adjacent to malignant tumor tissue was available for 159 of 279 breast cancer cases in the case-control study. The study was approved by the institutional review boards of the University of Hawaii and Wake Forest School of Medicine; all participants provided written informed consent. Further details of the study were reported previously (Verheus et al., 2009) . At entry into the MEC, all women completed a questionnaire that inquired about demographics, reproductive history, anthropometric measures, and family history of breast cancer. As part of the case-control study, women completed a one-page breast health questionnaire that asked about previous breast surgery, menopausal status, mammography history, and the use of hormone replacement therapy (HRT).
Tumor microarrays
Tissue microarrays (TMAs) were prepared according to standard procedures and immunostained separately for ERa (6G11; Novacastra Labs, Newcastle-upon-Tyne, UK) and ERb (EMR02; Novacastra Labs), PR (1A6; Novacastra Labs), HER2/neu (Rabbit Polyclonal; Dako Corporation, Carpinteria, California, USA), Ki-67 (Clone SP6; Labvision NeoMarkers, Fremont, California, USA), and PCNA (PC10; Novacastra Labs) as described elsewhere (Verheus et al., 2009 ). Among all stained specimens, 159 women were identified with at least one benign epithelial tissue sample. Missing data were recorded for PR and PCNA (N = 1); for ERa and ERb (N = 2); for Her2/neu (N = 3); and for Ki-67 (N = 4). A pathologic expert quantified staining on individual TMA core sections at a magnification of Â 20, using a Nikon Labophot 2 microscope, a 3 megapixel digital camera (Infinity 2-3; Lumenera Inc., Ottawa, Ontario, Canada), and color imaging software (Image Pro Plus; Media Cybernetics, Bethesda, Maryland, USA). Stromal tissue was not evaluated for any of these markers.
Statistical analysis
The SAS statistical software package version 9.2 was used for all analyses (SAS Institute Inc., Cary, North Carolina, USA). For all histology markers, the mean percentage of stained cells of all available cores per sample was calculated. For all six markers, the distributions of samples were skewed with strong left tails (Verheus et al., 2009) . Therefore, samples were divided into two categories: negative staining (< 10% of cells stained) and positive staining (Z 10% of cells stained). Because the number of women with positive staining for PR and Ki-67 was very low (4 and 13, respectively), we dichotomized the results by no vs. any epithelial staining. Given the known estrogen dependency of PR expression, we also compared the expression status of ER and PR in benign tissue using w 2 -tests. We used logistic regression models to examine marker expression (positive vs. negative) by parity category (0, 1-2, and Z 3 live births as continuous variable). Associations were adjusted for age at diagnosis (continuous) and BMI (kg/m 2 ). BMI was significantly associated with positive ERa expression (P trend = 0.02). Although age at first live birth was related to ERa expression (P trend < 0.01), it was not included as a covariate due to its high correlation with parity: 125 of 135 women (93%) had at least one live birth before or at 30 years. Menopausal status was also positively associated with parity because of the older age at diagnosis of parous than nulliparous women (Table 1) , but was not related to marker expression and, thus, not included as a covariate. We explored other potential breast cancer risk factors; that is, HRT use, physical activity, yearsof education, family history of breast cancer, ethnicity, age at menarche, alcohol consumption, and smoking, butno association with marker expression was detected. In addition, we performed stratified analyses by menopausal status and by ethnicity for the largest ethnic groups, that is, Whites and Japanese Americans. Subsequently, we evaluated the expression status of selected markers in malignant tissue that showed statistically significant associations with parity in benign tissue.
Results
Of the 159 women, 24 (15%) reported no children, 63 (40%) had one or two children, and 72 (45%) had three or more children (Table 1) . Japanese Americans constituted the largest proportion of participants, followed by Whites with smaller numbers of native Hawaiians and other ethnic backgrounds. Across parity categories, significant differences were noted for age at diagnosis (P < 0.001), HRT use (P < 0.01), menopausal status (P < 0.001), and age at first live birth (P < 0.0001). Women with children tended to be older at breast cancer diagnosis than nulliparous women (63.4±7.6 years for Z 3 children and 58.9±8.8 years for one or two children vs. 56.8±9.5 years for nulliparous women). HRT use was more common in women with three or more children (75%) than in women with no or one or two children (50 or 46%). Nearly all women (99%) with three or more children and 84% of the women with one or two children had their first child before the age of 30. No differences in BMI, years of education, family history of breast cancer, ethnicity, or age Parity and histopathologic markers in breast tissue Morimoto et al. 405 at menarche were apparent across parity categories. Expression of PR was not associated with ERa (49% in agreement; P = 0.95) and weakly associated with ERb (42% in agreement; P = 0.06).
We observed inverse associations between parity and positive expressions of ERa (P trend = 0.07) and PCNA (P trend = 0.04). Among nulliparous women, 45.5% were identified as ERa positive in contrast to 18.0 and 18.9% of women with one or two and three or more children, respectively. The respective values for PCNA were 56.5, 44.3, and 31.1%. The inverse associations became statistically significant (P trend = 0.02 for ERa and P trend = 0.04 for PCNA; Table 2 ) after adjustment for both age at diagnosis and BMI. Interestingly, stratified analyses by ethnicity showed similar trends in the 49 White women (75, 17, and 9% ERa positive across 0, 1-2, and Z 3 children; P trend < 0.01; 75, 41, and 30% PCNA positive; P trend = 0.03), but no association in the 70 Japanese Americans (33, 18, and 25% ERa positive; P trend = 0.47; 44, 41, and 38% PCNA positive; P trend = 0.78). However, the interaction terms between ethnicity and parity were not statistically significant (P interaction = 0.21 and 0.76). In stratified analyses by menopausal status, the inverse associations remained significant or borderline significant only for the 99 postmenopausal women (P trend = 0.01 for ERa and P trend = 0.08 for PCNA) and not for the 60 premenopausal women (P trend = 0.50 for ERa and P trend = 0.10 for PCNA), but again the interaction terms were not significant. In malignant tissue, neither the expression of ERa (P trend = 0.15) nor that of PCNA (P trend = 0.59) was associated with parity in both unadjusted and adjusted models.
No significant associations with parity were observed for ERb, PR, Her2/neu, and Ki-67 in unadjusted and adjusted models, even with different parity categories (0 vs. Z 1 or 0-2 vs. Z 3) or restricting the analyses to premenopausal or postmenopausal women only.
Discussion
In this exploratory study, parity was inversely associated with the expression of ERa and PCNA in benign tissue from a multiethnic population of premenopausal and postmenopausal breast cancer patients. The percentage of ERa staining was similar between the women with one or two and three or more children, suggesting a threshold effect; the percentage of nulliparous women with ERa positive staining was more than twice as high as that of parous women. In contrast, the percentage of PCNA staining showed a linear decline with the increasing number of children from 56.5 to 31.1%. No associations were detected for ERb, PR, Her2/ neu, and Ki-67. These findings support the idea that pregnancies modify the expression of hormonal and proliferation markers in the breast tissue in a manner that lowers breast cancer risk later in life.
The inverse association of parity with ERa expression in the present study was in agreement with a previous report (Taylor et al., 2009 ) that evaluated the expression of ERa and PRA and PRB in the breast terminal duct lobular unit epithelium of 26 premenopausal women and 30 pregnant women. In this study, lower expression of ERa was observed in 10 parous compared with 16 nulliparous premenopausal women, although the results were not statistically significant.
The mean percentage of ERa positive cells was lowest in parous women, intermediate in pregnant women, and highest in nulliparous women, indicating a transitional process during pregnancy. These observations support the hypothesis that a decline in hormone receptor positive cells occurs during breast maturation associated with pregnancy (Russo et al., 2005) . A recent study of nonhuman primates showed that ERa expression is diminished with parity and that ER-related markers including PR are markedly downregulated during pregnancy and lactation (Stute et al., 2012) . In contrast, no association between parity and ERa was seen in 158 normal breast samples from premenopausal women after adjustment for menstrual cycle phase and oral contraceptive use, which appear to influence ER expression (Battersby et al., 1992; Khan et al., 1998) . The heterogeneity by menopausal status observed in our study may be due to the lack of adjustment for menstrual cycle phase.
In contrast to our null findings even after stratification by menopausal status, trends of lower PR expression in parous vs. nulliparous women were observed elsewhere (Battersby et al., 1992; Taylor et al., 2009) . In particular, PRA was significantly lower in parous than in nulliparous premenopausal women (10.2 vs. 32.2% stained; P = 0.01).
The lack of such a pattern in the present study may be related to the unexpectedly weak associations of PR with ERa and ERb that were observed.
To our knowledge, no previous reports have described the association between parity and PCNA expression. PCNA is a nuclear protein expressed during cell cycle and plays a role in DNA synthesis (Leonardi et al., 1992; Schwartz et al., 1993; Malkas et al., 2006) . In previous studies, an overexpression of PCNA in tumor cells was associated with shorter overall survival, as well as with shorter diseasefree survival (Stuart-Harris et al., 2008) , but little is known about its relation to known breast cancer risk factors. Because PCNA is thought to assess longer-term, cumulative proliferative activity in cells (Leonardi et al., 1992) , an inverse relation with parity might reflect the pregnancyrelated reduction in cell growth in breast tissue.
The present study had several strengths including its multiethnic participants from a population-based cohort, the evaluation of benign tissue samples in tumor blocks of breast cancer patients, and the use of the TMA method.
More than half of the study population consisted of non-White women distributed evenly across parity categories. The overall sample size, although not ideal, was fairly large for a pathologic study that required access to tumor blocks and sufficient amounts of tissue. The TMA approach made it possible to examine multiple markers in specimens stained under identical conditions.
This study also had a number of limitations. Given the lack of readily available tissue samples and the invasive nature of breast biopsies, the study population did not include women without cancer to compare cases with controls. Because of field effects, benign tissues from unaffected women would have been preferable over benign tissue components from breast cancer patients. Concerns about statistical power did not allow more detailed stratified analyses by HRT use or breast cancer subtype. In addition, we did not adjust for age at first live birth because of serious collinearity with parity. Among the breast cancer cases included in the present study, the number of nulliparous women was relatively small. Thus, the findings should be interpreted with caution and need to be evaluated further in larger studies.
The results of this study suggest that ERa and PCNA in breast tissue reflect the cancer protective effects of pregnancies on the breast that reduce its susceptibility to estrogenic stimuli and proliferative activity. Although the potential mechanisms of action are unclear, these pathologic markers may be related to physiological changes in the breast associated with parity.
